References
- Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol [Internet]. 2004;93(1):204–208. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15047237
- Kurman R. WHO classification of tumours of female reproductive organs [Internet]. 4th ed. Lyon: International Agency for Research on Cancer; 2014. Available from: http://worldcatlibraries.org/wcpa/oclc/885200492
- Hagiyama Y, Hashimoto H, Hamada K, et al. Embryonal rhabdomyosarcoma of the uterus in a 35-year-old woman: case report and review of the literature. Eur J Gynaecol Oncol [Internet]. 2013;34(4):332–335. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24020141
- Kim DW, Shin JH, Lee HJ, et al. Spindle cell rhabdomyosacoma of uterus: a case study. Korean J Pathol [Internet]. 2013;47(4):388–391. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3759640
- Ditto A, Martinelli F, Carcangiu M, et al. Embryonal rhabdomyosarcoma of the uterine cervix in adults: a case report and literature review. J Low Genit Tract Dis [Internet]. 2013;17(4):e12–e17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23903199
- Jain S, Jain K, Chopra P. Embryonal rhabdomyosarcoma of the uterine cervix in a 41-year-old woman: a deceptively benign entity. Int J Gynecol Pathol [Internet]. 2013;32(4):421–425. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23722516
- Cate F, Bridge JA, Crispens MA, et al. Composite uterine neoplasm with embryonal rhabdomyosarcoma and primitive neuroectodermal tumor components: rhabdomyosarcoma with divergent differentiation, variant of primitive neuroectodermal tumor, or unique entity? Hum Pathol [Internet]. 2013;44(4):656–663. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23266445
- Garrett LA, Harmon DC, Schorge JO. Embryonal rhabdomyosarcoma of the uterine corpus. J Clin Oncol [Internet]. 2013;31(4):e48–e50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23248250
- Fadare O, Khabele D. Pleomorphic liposarcoma of the uterine corpus with focal smooth muscle differentiation. Int J Gynecol Pathol [Internet]. 2011;33(3):282–287. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21464725
- Schoolmeester JK, Sciallis AP, Greipp PT, et al. Analysis of MDM2 amplification in 43 endometrial stromal tumors: a potential diagnostic pitfall. Int J Gynecol Pathol [Internet]. 2015;34(6):576–583. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26444253
- Lavie O, Barnett-Griness O, Narod SA, et al. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer [Internet]. 2008;18(2):352–356. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18334013
- Committee opinion no. 601: tamoxifen and uterine cancer. Obstet Gynecol [Internet]. 2014;123(6):1394–1397. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24848920
- Sumi A, Terasaki H, Sanada S, et al. Assessment of MR imaging as a tool to differentiate between the major histological types of uterine sarcomas. Magn Reson Med Sci [Internet]. 2015;14(4):295–304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26104072
- Park GE, Rha SE, Oh SN, et al. Ultrasonographic findings of low-grade endometrial stromal sarcoma of the uterus with a focus on cystic degeneration. Ultrason (Seoul, Korea) [Internet]. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26537303
- Oliva E. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia. Mod Pathol [Internet]. 2016;29(Suppl 1):S104–S120. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26715170
- Oliva E. Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol [Internet]. 2014;33(4):374–384. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24901397
- Bernheim A. Cytogenomics of cancers: from chromosome to sequence. Mol Oncol [Internet]. 2010;4(4):309–322. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20599448
- Barlin JN, Zhou QC, Leitao MM, et al. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. Neoplasia [Internet]. 2015;17(2):183–189. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4351299
- Gibault L, Pérot G, Chibon F, et al. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol [Internet]. 2011;223(1):64–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21125665
- Croce S, Ribeiro A, Brulard C, et al. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Mod Pathol [Internet]. 2015;28:1001–1010. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25932961
- Hicks J, Krasnitz A, Lakshmi B, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res [Internet]. 2006;16(12):1465–1479. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1665631
- Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell [Internet]. 2011;144(1):27–40. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3065307
- Mehine M, Kaasinen E, Mäkinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med [Internet]. 2013;369(1):43–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23738515
- Holzmann C, Markowski DN, Koczan D, et al. Cytogenetically normal uterine leiomyomas without MED12-mutations - a source to identify unknown mechanisms of the development of uterine smooth muscle tumors. Mol Cytogenet [Internet]. 2014;7(1):88. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4264251&tool=pmcentrez&rendertype=abstract
- Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science [Internet]. 2011;334(6053):252–255. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21868628
- Markowski DN, Bartnitzke S, Löning T, et al. MED12 mutations in uterine fibroids - their relationship to cytogenetic subgroups. Int J Cancer [Internet]. 2012;131(7):1528–1536. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22223266
- Bertsch E, Qiang W, Zhang Q, et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol [Internet]. 2014;27(8):1144–1153. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4081525
- Klemke M, Meyer A, Nezhad MH, et al. Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer [Internet]. 2009;48(2):171–178. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18980243
- Klemke M, Müller MH, Wosniok W, et al. Correlated expression of HMGA2 and PLAG1 in thyroid tumors, uterine leiomyomas and experimental models. Plos One [Internet]. 2014;9(2):e88126. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3917869
- Schoenmakers EFPM, Wanschura S, Mols R, et al. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet [Internet]. 1995;10(4):436–444. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7670494
- Ordulu Z, Nucci MR, Dal Cin P, et al. Intravenous leiomyomatosis: an unusual intermediate between benign and malignant uterine smooth muscle tumors. Mod Pathol [Internet]. 2016;29(5):500–510. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26892441
- Pérot G, Croce S, Ribeiro A, et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. Plos One [Internet]. 2012;7(6):e40015. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3386951
- Kämpjärvi K, Mäkinen N, Kilpivaara O, et al. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer [Internet]. 2012;107(10):1761–1765. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3493861
- Ravegnini G, Mariño-Enriquez A, Slater J, et al. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol. 2013;26(5):743–749. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23222489
- Markowski DN, Huhle S, Nimzyk R, et al. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors. Genes Chromosomes Cancer [Internet]. 2013;52(3):297–304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23225304
- Kazmierczak B, Bol S, Wanschura S, et al. PAC clone containing the HMGI(Y) gene spans the breakpoint of a 6p21 translocation in a uterine leiomyoma cell line. Genes Chromosomes Cancer [Internet]. 1996;17(3):191–193. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8946199
- Vanharanta S, Wortham NC, Langford C, et al. Definition of a minimal region of deletion of chromosome 7 in uterine leiomyomas by tiling-path microarray CGH and mutation analysis of known genes in this region. Genes Chromosomes Cancer [Internet]. 2007;46(5):451–458. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17285575
- Sell SM, Tullis C, Stracner D, et al. Minimal interval defined on 7q in uterine leiomyoma. Cancer Genet Cytogenet [Internet]. 2005;157(1):67–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15676150
- Mittal P, Shin Y-H, Yatsenko SA, et al. Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest [Internet]. 2015;125(8):3280–3284. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26193636
- Yang EJ, Mutter GL. Biomarker resolution of uterine smooth muscle tumor necrosis as benign vs malignant. Mod Pathol [Internet]. 2015;28(6):830–835. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25698060
- Lim D, Alvarez T, Nucci MR, et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol [Internet]. 2013;37(5):650–658. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23552382
- Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst [Internet]. 1986;76(3):399–402. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3456457
- Francis M, Dennis NL, Hirschowitz L, et al. Incidence and survival of gynecologic sarcomas in England. Gynecol Surg [Internet]. 2015;12(3):165–177. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4532723
- Pritts EA, Vanness DJ, Berek JS, et al.The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol Surg [Internet]. 2015;12(3):165–177. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26283890
- Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol [Internet]. 2008;198(2):218.e1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18226630
- Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer [Internet]. 2008;112(4):820–830. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18189292
- Markowski DN, Tadayyon M, Bartnitzke S, et al. Cell cultures in uterine leiomyomas: rapid disappearance of cells carrying MED12 mutations. Genes Chromosom Cancer [Internet]. 2014;53(4):317–323. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24446130
- Holzmann C, Markowski DN, Koczan D, et al. Genome-wide acquired uniparental disomy as well as chromosomal gains and losses in an uterine epithelioid leiomyoma. Mol Cytogenet [Internet]. 2014;7(1):19. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3996012
- Holzmann C, Markowski DN, Bartnitzke S, et al. A rare coincidence of different types of driver mutations among uterine leiomyomas (UL). Mol Cytogenet [Internet]. 2015;8(1):76–82. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4604635&tool=pmcentrez&rendertype=abstract
- Holzmann C, Markowski DN, von Leffern I, et al. Patterns of chromosomal abnormalities that can improve diagnosis of uterine smooth muscle tumors. Anticancer Res [Internet]. 2015;35(12):6445–6456. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26637855
- Hodge JC, Pearce KE, Clayton AC, et al. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol [Internet]. 2014;210(6):572.e1–572.e7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4040311
- Ylipää A, Hunt KK, Yang J, et al. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer [Internet]. 2011;117(2):380–389. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3008331
- Schaefer I-M, Delfs C, Cameron S, et al. Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors. Hum Pathol [Internet]. 2014;45(1):85–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24157063
- Lartigue L, Neuville A, Lagarde P, et al. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy. Eur J Cancer [Internet]. 2015;51(1):75–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25466504
- Boghosian L, Dal Cin P, Turc-Carel C, et al. Three possible cytogenetic subgroups of leiomyosarcoma. Cancer Genet Cytogenet [Internet]. 1989;43(1):39–49. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2790771
- Bardi G, Johansson B, Pandis N, et al. Recurrent chromosome aberrations in abdominal smooth muscle tumors. Cancer Genet Cytogenet [Internet]. 1992;62(1):43–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1521232
- Sreekantaiah C, Davis JR, Sandberg AA. Chromosomal abnormalities in leiomyosarcomas. Am J Pathol [Internet]. 1993;142(1):293–305. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1886846
- Mark J, Wedell B, Dahlenfors R, et al. Cytogenetic observations in a human gastric leiomyosarcoma. Cancer Genet Cytogenet [Internet]. 1989;37(2):215–220. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2702621
- Pandis N, Heim S, Bardi G, et al. Chromosome analysis of 96 uterine leiomyomas. Cancer Genet Cytogenet [Internet]. 1991;55(1):11–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1913597
- Hu J, Surti U. Subgroups of uterine leiomyomas based on cytogenetic analysis. Hum Pathol [Internet]. 1991;22(10):1009–1016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1842373
- Zhai Y-L, Nikaido T, Orii A, et al. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol [Internet]. 1999;75(3):453–459. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10600306
- Raish M, Khurshid M, Ansari MA, et al. Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization. J Cancer Res Clin Oncol [Internet]. 2012;138(7):1173–1186. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22419440
- Nilbert M, Mandahl N, Heim S, et al. Cytogenetic abnormalities in an angioleiomyoma. Cancer Genet Cytogenet [Internet]. 1989;37(1):61–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2917333
- Meloni AM, Surti U, Sandberg AA. Deletion of chromosome 13 in leiomyomas of the uterus. Cancer Genet Cytogenet [Internet]. 1991;53(2):199–203. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2065294
- Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genet Cytogenet [Internet]. 2005;158(1):1–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15771900
- Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A [Internet]. 1971;68(4):820–823. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=389051
- Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature [Internet]. 2011;476(7359):163–169. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3206311
- Francis JH, Kleinerman RA, Seddon JM, et al. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. Gynecol Oncol [Internet]. 2012;124(2):254–259. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3264733
- Liu Y, Sánchez-Tilló E, Lu X, et al. Rb1 family mutation is sufficient for sarcoma initiation. Nat Commun [Internet]. 2013;4:2650. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24150016
- Hall KL, Teneriello MG, Taylor RR, et al. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol [Internet]. 1997;65(2):330–335. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9159347
- Zhang Q, Ubago J, Li L, et al. Molecular analyses of 6 different types of uterine smooth muscle tumors: emphasis in atypical leiomyoma. Cancer [Internet]. 2014;120:3165–3177. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24986214
- Markowski DN, Nimzyk R, Belge G, et al. Molecular topography of the MED12-deleted region in smooth muscle tumors: a possible link between non-B DNA structures and hypermutability. Mol Cytogenet [Internet]. 2013;6(1):23. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3712005
- Mäkinen N, Vahteristo P, Bützow R, et al. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas. Int J Cancer [Internet]. 2014;134(4):1008–1012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23913526
- Turunen M, Spaeth JM, Keskitalo S, et al. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep [Internet]. 2014;7(3):654–660. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4041330
- Mäkinen N, Vahteristo P, Kämpjärvi K, et al. MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur J Hum Genet [Internet]. 2013;21(11):1300–1303. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3798840
- Mandahl N, Johansson B, Mertens F, et al. Disease-associated patterns of disomic chromosomes in hyperhaploid neoplasms. Genes Chromosomes Cancer [Internet]. 2012;51(6):536–544. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22334476
- Nord KH, Paulsson K, Veerla S, et al. Retained heterodisomy is associated with high gene expression in hyperhaploid inflammatory leiomyosarcoma. Neoplasia [Internet]. 2012;14(9):807–812. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3459276
- Chiang S, Oliva E. Cytogenetic and molecular aberrations in endometrial stromal tumors. Hum Pathol [Internet]. 2011;42(5):609–617. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21420714
- Chiang S, Ali R, Melnyk N, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol [Internet]. 2011;35(9):1364–1372. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21836477
- Oliva E, de Leval L, Soslow RA, et al. High frequency of JAZF1-JJAZ1 gene fusion in endometrial stromal tumors with smooth muscle differentiation by interphase FISH detection. Am J Surg Pathol [Internet]. 2007;31(8):1277–1284. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17667554
- Nucci MR, Harburger D, Koontz J, et al. Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol [Internet]. 2007;31(1):65–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17197920
- Sreekantaiah C, Li FP, Weidner N, et al. An endometrial stromal sarcoma with clonal cytogenetic abnormalities. Cancer Genet Cytogenet [Internet]. 1991;55(2):163–166. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1933818
- Dal Cin P, Aly MS, De Wever I, et al. Endometrial stromal sarcoma t(7;17)(p15-21;q12-21) is a nonrandom chromosome change. Cancer Genet Cytogenet [Internet]. 1992;63(1):43–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1423225
- Hennig Y, Caselitz J, Bartnitzke S, et al. A third case of a low-grade endometrial stromal sarcoma with a t(7;17)(p14∼21;q11.2∼21). Cancer Genet Cytogenet. 1997;98(1):84–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9309124
- Micci F, Walter CU, Teixeira MR, et al. Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet Cytogenet [Internet]. 2003;144(2):119–124. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12850374
- Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A [Internet]. 2001;98(11):6348–6353. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=33471
- Micci F, Panagopoulos I, Bjerkehagen B, et al. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res [Internet]. 2006;66(1):107–112. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16397222
- Panagopoulos I, Micci F, Thorsen J, et al. Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. Plos One [Internet]. 2012;7(6):e39354. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3382230
- Micci F, Gorunova L, Gatius S, et al. MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma. Cancer Lett [Internet]. 2014;347(1):75–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24530230
- D’Angelo E, Ali RH, Espinosa I, et al. Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement. Am J Surg Pathol [Internet]. 2013;37(4):514–521. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23211293
- Dewaele B, Przybyl J, Quattrone A, et al. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer [Internet]. 2014;134(5):1112–1122. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23959973
- Panagopoulos I, Thorsen J, Gorunova L, et al. Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer [Internet]. 2013;52(7):610–618. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23580382
- Hennig Y, Caselitz J, Stern C, et al. Karyotype evolution in a case of uterine angioleiomyoma. Cancer Genet Cytogenet [Internet]. 1999;108(1):79–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9973929
- Lee C-H, Nucci MR. Endometrial stromal sarcoma - the new genetic paradigm. Histopathology [Internet]. 2014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25355621
- Lee C-H, Mariño-Enriquez A, Ou W, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol [Internet]. 2012;36(5):641–653. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22456610
- Lee C-H, Ou W-B, Marino-Enriquez A, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A [Internet]. 2012;109(3):929–934. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3271913
- Leunen K, Amant F, Debiec-Rychter M, et al. Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation. Gynecol Oncol [Internet]. 2003;91(1):265–271. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14529693
- Suzuki S, Tanioka F, Minato H, et al. Breakages at YWHAE, FAM22A, and FAM22B loci in uterine angiosarcoma: a case report with immunohistochemical and genetic analysis. Pathol Res Pract [Internet]. 2014;210(2):130–134. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24125656
- Isphording A, Ali RH, Irving J, et al. YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin-embedded tumor. Hum Pathol [Internet]. 2013;44(5):837–843. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23159154
- Conklin CMJ, Longacre TA. Endometrial stromal tumors: the new WHO classification. Adv Anat Pathol [Internet]. 2014;21(6):383–393. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25299308
- O’Meara E, Stack D, Lee C-H, et al. Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol [Internet]. 2012;227(1):72–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22294382
- Fehr A, Hansson MC, Kindblom L-G, et al. YWHAE-FAM22 gene fusion in clear cell sarcoma of the kidney. J Pathol [Internet]. 2012;227(4):e5–e7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22544441
- Dal Cin P, Boghosian L, Crickard K, et al. t(10;17) as the sole chromosome change in a uterine leiomyosarcoma. Cancer Genet Cytogenet [Internet]. 1988;32(2):263–266. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3163264
- Sciallis AP, Bedroske PP, Schoolmeester JK, et al. High-grade endometrial stromal sarcomas: a clinicopathologic study of a group of tumors with heterogenous morphologic and genetic features. Am J Surg Pathol [Internet]. 2014;38(9):1161–1172. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25133706
- Pautier P, Nam EJ, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus. Int J Gynecol Cancer [Internet]. 2014;24(9 Suppl 3):S73–S77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25341584
- Gremel G, Liew M, Hamzei F, et al. A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer [Internet]. 2015;136(7):1608–1618. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25130488
- Stewart CJR, Leung YC, Murch A, et al. Evaluation of fluorescence in-situ hybridization in monomorphic endometrial stromal neoplasms and their histological mimics: a review of 49 cases. Histopathology [Internet]. 2014;65(4):473–482. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24592973
- Flicker K, Smolle E, Haybaeck J, et al. Genomic characterization of endometrial stromal sarcomas with array comparative genomic hybridization. Exp Mol Pathol [Internet]. 2015;98(3):367–374. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25758203
- Carroll A, Ramirez PT, Westin SN, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol [Internet]. 2014;135(3):455–461. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25449308
- Storlazzi CT, Mertens F, Domanski H, et al. Ring chromosomes and low-grade gene amplification in an atypical lipomatous tumor with minimal nuclear atypia. Int J Oncol [Internet]. 2003;23(1):67–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12792777
- Mandahl N, Bartuma H, Magnusson L, et al. HMGA2 and MDM2 expression in lipomatous tumors with partial, low-level amplification of sequences from the long arm of chromosome 12. Cancer Genet [Internet]. 2011;204(10):550–556. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22137485
- Hostein I, Pelmus M, Aurias A, et al. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol [Internet]. 2004;202(1):95–102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14694526
- Thway K, Wang J, Swansbury J, et al. Fluorescence in situ hybridization for MDM2 amplification as a routine ancillary diagnostic tool for suspected well-differentiated and dedifferentiated liposarcomas: experience at a tertiary center. Sarcoma [Internet]. 2015;2015:812089. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4355609
- Nord KH, Macchia G, Tayebwa J, et al. Integrative genome and transcriptome analyses reveal two distinct types of ring chromosome in soft tissue sarcomas. Hum Mol Genet [Internet]. 2014;23(4):878–888. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24070870
- Piscuoglio S, Burke KA, Ng CK, et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol [Internet]. 2016;238(3):381–388. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26592504
- Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer [Internet]. 2010;49(3):224–236. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2808450
- Bashir S, Jiang G, Joshi A, et al. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors. Int J Gynecol Cancer [Internet]. 2014;24(7):1262–1267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25078343
- Growdon WB, Roussel BN, Scialabba VL, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol [Internet]. 2011;121(1):212–217. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21168197
- Lopez-Garcia M-A, Palacios J. Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol [Internet]. 2010;27(4):274–286. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21309261
- Fles R, Hoogendoorn WE, Platteel I, et al. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer [Internet]. 2010;49(8):699–710. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20544844
- Harel M, Ferrer FA, Shapiro LH, et al. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma. Urol Oncol [Internet]. 2016;34(2):103–115. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26519985
- Yamada S, Harada Y, Noguchi H, et al. Embryonal rhabdomyosarcoma arising from the uterine corpus in a postmenopausal female: a surgical case challenging the genuine diagnosis on a cytology specimen. Diagn Pathol [Internet]. 2016;11(1):3. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4709879
- Singh SS, Scott S, Bougie O, et al. Technical update on tissue morcellation during gynaecologic surgery: its uses, complications, and risks of unsuspected malignancy. J Obstet Gynaecol Canada JOGC [Internet]. 2015;37(1):68–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25764040
- Zhang J, Li T, Zhang J, et al. Clinical characteristics and prognosis of unexpected uterine sarcoma after hysterectomy for presumed myoma with and without transvaginal scalpel morcellation. Int J Gynecol Cancer [Internet]. 2016;26:456–463. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26807642
- Perkins RB, Handal-Orefice R, Hanchate AD, et al. Risk of undetected cancer at the time of laparoscopic supracervical hysterectomy and laparoscopic myomectomy: implications for the use of power morcellation. Womens Health Issues [Internet]. 2016;26(1):21–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26701205
- Bogani G, Chiappa V, Ditto A, et al. Morcellation of undiagnosed uterine sarcoma: a critical review. Crit Rev Oncol Hematol [Internet]. 2016;98:302–308. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26672915
- Hrzenjak A, Dieber-Rotheneder M, Moinfar F, et al. Molecular mechanisms of endometrial stromal sarcoma and undifferentiated endometrial sarcoma as premises for new therapeutic strategies. Cancer Lett [Internet]. 2014;354(1):21–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25128649
- Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res [Internet]. 2014;20(13):3379–3383. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24795392
- Cuppens T, Tuyaerts S, Amant F. Potential therapeutic targets in uterine sarcomas. Sarcoma [Internet]. 2015;2015:243298. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4632006